Quantitative bias analysis of a reported association between perfluoroalkyl substances (PFAS) and endometriosis: The influence of oral contraceptive use

Gérard Ngueta, Gerard Ngueta, Ngueta G, Matthew P. Longnecker, Longnecker MP, Miyoung Yoon, Yoon M, Christopher D. Ruark, Harvey J. Clewell, Clewell HJ Rd, Melvin E. Andersen, Marc-André Verner, Verner MA
Environment international · 2017 · vol. 104 , pp. 118–121 · doi:10.1016/j.envint.2017.03.023 · PMID:28392065 · W2605244600
article OA: closed CC0 ⤵ 1 in-corpus citation
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This study investigated how oral contraceptive use might bias associations between perfluoroalkyl substances (PFAS) and endometriosis, finding that accounting for this bias influences the observed relationship.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

An association between serum levels of perfluoroalkyl substances (PFAS) and endometriosis has recently been reported in an epidemiologic study. Oral contraceptive use to treat dysmenorrhea (pelvic pain associated with endometriosis) could potentially influence this association by reducing menstrual fluid loss, a route of excretion for PFAS. In this study, we aimed to evaluate the influence of differential oral contraceptive use on the association between PFAS and endometriosis. We used a published life-stage physiologically based pharmacokinetic (PBPK) model to simulate plasma levels of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) from birth to age at study participation (range 18-44years). In the simulated population, PFAS level distributions matched those for controls in the epidemiologic study. Prevalence and geometric mean duration (standard deviation [SD]) of oral contraceptive use in the simulated women were based on data from the National Health and Nutrition Examination Survey; among the women with endometriosis the values were, respectively, 29% and 6.8 (3.1) years; among those without endometriosis these values were 18% and 5.3 (2.8) years. In simulations, menstrual fluid loss (ml/cycle) in women taking oral contraceptives was assumed to be 56% of loss in non-users. We evaluated the association between simulated plasma PFAS concentration and endometriosis in the simulated population using logistic regression. Based on the simulations, the association between PFAS levels and endometriosis attributable to differential contraceptive use had an odds ratio (95% CI) of 1.05 (1.02, 1.07) for a loge unit increase in PFOA and 1.03 (1.02, 1.05) for PFOS. In comparison, the epidemiologic study reported odds ratios of 1.62 (0.99, 2.66) for PFOA and 1.25 (0.87, 1.80) for PFOS. Our results suggest that the influence of oral contraceptive use on the association between PFAS levels and endometriosis is relatively small.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Alkanesulfonic Acids Caprylates Contraceptives, Oral Endometriosis Endometriosis Endometriosis Endometriosis Environmental Pollutants Fluorocarbons Adult Alkanesulfonic Acids Bias Caprylates Contraceptives, Oral Environmental Monitoring Environmental Pollutants Female Fluorocarbons Humans Nutrition Surveys

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (4)

Cited by (2)

References (18)

Cited by (2)

Source provenance

europepmc
last seen: 2026-08-15T06:15:18.721777+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:20:31.759405+00:00
unpaywall
last seen: 2026-08-15T06:29:46.044917+00:00
License: CC0 · commercial use OK